This activity is expired and is no longer available for CME credit.


Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

Author(s)/Faculty: Daniel P. Petrylak, MD; David I. Quinn, MD, PhD, FRACP, FACP; Jonathan E. Rosenberg, MD; Walter M. Stadler, MD, FACP
Release Date: 4/3/2017Expiration Date: 4/2/2018
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised to cause a paradigm shift in the near future. Therefore, it is of utmost importance that oncologists who treat patients with bladder cancer are ready and able to incorporate these agents into practice. In this CME activity, leading oncologists will discuss the latest treatment strategies, clinical advances, and targeted therapies for the treatment of advanced bladder cancer.